JPRN-UMIN000003645已完成2 期
Phase II study of CDDP/Alimuta combined with bevacizumab in patients with advanced non-small-cell lung cancer without harboring sensitive EGFR mutations - ALPS trial
Department of Comprehensive Cancer Therapy, Shinshu Universituy School of Medicine0 个研究点目标入组 50 人开始时间: 2011年1月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) pulmonary fibrosis on chest radiograph, 2)active infection, 3) severe heart disease, 4) past history of hypersensitivity to drugs, 5) pleural or pericardial effusion that required drainage, 6) brain metastasis or 7) pregnancy. Patients with a concomitant active malignancy were also excluded. Other concomitant anticancer therapy or experimental drug administration of any type was not permitted.
研究者
相似试验
进行中（未招募）
1 期
Phase I-II study of low dose CdA combined with valproic acid (VPA) in previously treated B-cell chronic lymphocytic leukemia (CLL) patients. - VPA-CdA in C•B-CLL, as defined by the NCIWG criteria •Patients must have intermediate or high-risk categories of the modified 3-stage Rai and Binet stagingsMedDRA version: 14.0Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019983-35-BECliniques universitaires Saint Luc33
招募中
2 期
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll LPrimary Plasma Cell LeukemiaNCT06636552Hellenic Society of Hematology43
招募中
不适用
Phase II study of the 2nd line Nab-PTX/CBDCA combination therapy for advanced non-small cell lung cancer which is previously treated with platinum-based chemotherapyon-small cell lung cancerJPRN-UMIN000011669Dokkyo Medical University40
进行中（未招募）
1 期
Study of dabrafenib+trametinib in the Adjuvant treatment of stage III BRAF V600+ melanoma after complete resection to evaluate the impact on pyrexia related outcomesStage III BRAF V600 mutation-positive melanomaMedDRA version: 21.1Level: PTClassification code 10025650Term: Malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000168-27-HUovartis Pharma AG600
进行中（未招募）
1 期
Study of dabrafenib+trametinib in the Adjuvant treatment of stage III BRAF V600+ melanoma after complete resection to evaluate the impact on pyrexia related outcomesStage III BRAF V600 mutation-positive melanomaMedDRA version: 21.1Level: PTClassification code 10025650Term: Malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-000168-27-LTovartis Pharma AG600